Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

v3.6.0.2
Subsequent Events - Additional Information (Detail) - Subsequent Event [Member]
$ in Millions
 1 Months Ended
Jan. 05, 2017
USD ($)
Right
shares
Jan. 04, 2017
Jan. 31, 2017
Subsequent Event [Line Items]      
Reversion rights period     90 days
Achieve Life Science, Inc. [Member]      
Subsequent Event [Line Items]      
Conversion of each outstanding share of Achieve common stock , shares converted | shares 4,242.8904    
Termination fee $ 0.5    
Termination fee upon breach of certain covenants regarding alternative transactions 1.0    
Third party expenses in connection with certain terminations $ 0.5    
Lock-up period with the execution of the merger agreement   180 days  
Number of contingent value rights to be issued for each share of common stock outstanding | Right 1    
Achieve Life Science, Inc. [Member] | Contingent Value Rights [Member]      
Subsequent Event [Line Items]      
Combined company acquisition period results 5 years    
Aggregate consideration distributed to the holders, consideration received percent 80.00%    
OncoGenex Pharmaceuticals Equityholders [Member] | Achieve Life Science, Inc. [Member]      
Subsequent Event [Line Items]      
Percentage of ownership in combined company 25.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors   1.20%  
Achieve Stockholders [Member] | Achieve Life Science, Inc. [Member]      
Subsequent Event [Line Items]      
Percentage of ownership in combined company 75.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors   78.00%